Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...

A diagnosis of ATTR-CM in a more recent era was associated with older age, White race, wild‐type disease, and tafamidis treatment. The survival of patients diagnosed with transthyretin-mediated ...

Angela Ryan Lee, MD, FACC, is a board-certified cardiology and internal medicine physician. She also holds board certifications from the American Society of Nuclear Cardiology and the National Board ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

Sleep problems are extremely common when you’re living with transthyretin amyloid cardiomyopathy (ATTR-CM). This heart condition involves misshapen transthyretin protein building up in your heart ...

Over time, transthyretin amyloidosis (ATTR) can damage the nerves, heart, and other organs. This may lead to complications like heart problems, nerve damage, and trouble with everyday bodily functions ...